Drugs / DISC-3405
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07187973 | Jan 2026 → Jun 2027 expected | sickle cell disease | Disc Medicine, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06050915 | Oct 2023 → Jul 2024 | — | Disc Medicine, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06985147 | Aug 2025 → Feb 2027 expected | acquired polycythemia vera | Disc Medicine, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Disc Medicine, Inc | Results Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting discmedicine.com ↗
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV). |
| 2024-06-14 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress discmedicine.com ↗
Disc also shared initial SAD data from a Phase 1 healthy volunteer trial of DISC-3405 that provided proof of mechanism, showing that the drug has the potential to provide deep and sustained increases in hepcidin and reductions in iron. |
| 2024-02-09 | Disc Medicine, Inc | Regulatory Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera discmedicine.com ↗
today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DISC-3405 for the treatment of patients with polycythemia vera (PV). |
| 2023-09-20 | Disc Medicine, Inc | Regulatory Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera discmedicine.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Disc Medicine, Inc | Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting discmedicine.com ↗ |
| 2024-06-14 | Disc Medicine, Inc | Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress discmedicine.com ↗ |
| 2024-02-09 | Disc Medicine, Inc | Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera discmedicine.com ↗ |
| 2023-10-03 | Disc Medicine, Inc | Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers discmedicine.com ↗ |
| 2023-09-20 | Disc Medicine, Inc | Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera discmedicine.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DISC-3405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06985147 ↗ |
| Route | Intravenous | “IV infusion” NCT06050915 ↗ |